Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Toxic delirium after L-dopa medication.

W Birkmayer

    Journal of Neural Transmission. Supplementum
    |January 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    L-DOPA-psychosis, a side effect of Parkinson's disease treatment, is linked to increased noradrenaline and serotonin in specific brain areas. These neurotransmitter changes outside the lenticular nuclei may explain associated psychiatric disorders.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    4-HYDROXY-3-METHOXYPHENYLGLYCOL AS AN INDEX OF BRAIN NORADRENALINE TURNOVER IN ENDOGENOUS DEPRESSION.

    Acta psychiatrica Scandinavica·2017
    Same author

    [Society for Study of the Autonomic Nervous System; meetings of 22 November and 13 December 1949].

    Acta neurovegetativa·2014
    Same author

    About the concept of vegetative ataxia.

    Wiener medizinische Wochenschrift (1946)·2010
    Same author

    The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism.

    Parkinsonism & related disorders·2008
    Same author

    The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961.

    Wiener klinische Wochenschrift·2002
    Same author

    Nicotinamide adenine dinucleotide (NADH)--a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application.

    Acta neurologica Scandinavica. Supplementum·1993

    Area of Science:

    • Neuroscience
    • Psychiatry
    • Pharmacology

    Background:

    • L-DOPA-psychosis is a common adverse effect in Parkinson's disease patients treated with L-DOPA and decarboxylase inhibitors.
    • Previous research suggests neurotransmitter imbalances may underlie L-DOPA-induced psychosis.

    Purpose of the Study:

    • To investigate regional neurotransmitter changes in the brains of individuals experiencing L-DOPA-psychosis.
    • To explore the correlation between extrastriatal neurotransmitter alterations and psychiatric symptoms.

    Main Methods:

    • Analysis of post-mortem human brain tissue.
    • Measurement of noradrenaline and serotonin levels in specific brain regions.

    Main Results:

    • A significant increase in noradrenaline and serotonin was observed in extrastriatal brain areas.

    Related Experiment Videos

  • No significant changes in neurotransmitter levels were found in the lenticular nuclei.

    • Conclusions:

    • Extrastriatal neurotransmitter dysfunctions, specifically elevated noradrenaline and serotonin, are associated with L-DOPA-psychosis.
    • These findings highlight the potential role of extrastriatal neurochemical alterations in the psychiatric complications of Parkinson's disease treatment.